Professor Manfred Auer

Manfred Auer’s research is focused on the development and application of miniaturised, ultra-high throughput screening platforms for the identification and validation of lead compounds for drug discovery and tool compounds for basic research. His “Integrated Chemical Biophysics” platforms (ICB) include in-silico design and screening, tagged one-bead one compound library production and screening on the surface of beads and chips, in solution, in cells and in model organisms. ICB platforms combine chemical, biological, and physical approaches to overcome many of the limitations of the current industrial early drug-discovery process. Using the flexible post-synthesis – post screening tagging technologies developed in the Auer group, both label free and single molecule fluorescence detection technologies are combined into seamless processes. Manfred Auer was previously Executive Director of the Innovative Screening Technologies Unit at the Novartis Institutes of Biomedical Research. He has 20 years experience leading research in the pharmaceutical industry. In 2002, he received the Society for Biomolecular Screening Achievement Award for his pioneering work in confocal fluorescence technologies and their application to high throughput screening platforms.